-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case
With EPS Growth And More, Raffles Medical Group (SGX:BSL) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.
So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Raffles Medical Group (SGX:BSL). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.
See our latest analysis for Raffles Medical Group
How Fast Is Raffles Medical Group Growing?
The market is a voting machine in the short term, but a weighing machine in the long term, so you'd expect share price to follow earnings per share (EPS) outcomes eventually. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. Raffles Medical Group managed to grow EPS by 15% per year, over three years. That's a pretty good rate, if the company can sustain it.
Top-line growth is a great indicator that growth is sustainable, and combined with a high earnings before interest and taxation (EBIT) margin, it's a great way for a company to maintain a competitive advantage in the market. The music to the ears of Raffles Medical Group shareholders is that EBIT margins have grown from 15% to 19% in the last 12 months and revenues are on an upwards trend as well. Both of which are great metrics to check off for potential growth.
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
SGX:BSL Earnings and Revenue History September 14th 2022While we live in the present moment, there's little doubt that the future matters most in the investment decision process. So why not check this interactive chart depicting future EPS estimates, for Raffles Medical Group?
Are Raffles Medical Group Insiders Aligned With All Shareholders?
Investors are always searching for a vote of confidence in the companies they hold and insider buying is one of the key indicators for optimism on the market. That's because insider buying often indicates that those closest to the company have confidence that the share price will perform well. However, small purchases are not always indicative of conviction, and insiders don't always get it right.
One gleaming positive for Raffles Medical Group, in the last year, is that a certain insider has buying shares with ample enthusiasm. Specifically, in one large transaction Executive Chairman & CEO Choon Yong Loo paid S$1.8m, for stock at S$1.19 per share. Seeing such high conviction in the company is a huge positive for shareholders and should instil confidence in their mission.
Along with the insider buying, another encouraging sign for Raffles Medical Group is that insiders, as a group, have a considerable shareholding. We note that their impressive stake in the company is worth S$330m. That equates to 13% of the company, making insiders powerful and aligned with other shareholders. Looking very optimistic for investors.
Is Raffles Medical Group Worth Keeping An Eye On?
As previously touched on, Raffles Medical Group is a growing business, which is encouraging. Better yet, insiders are significant shareholders, and have been buying more shares. That makes the company a prime candidate for your watchlist - and arguably a research priority. Of course, identifying quality businesses is only half the battle; investors need to know whether the stock is undervalued. So you might want to consider this free discounted cashflow valuation of Raffles Medical Group.
There are plenty of other companies that have insiders buying up shares. So if you like the sound of Raffles Medical Group, you'll probably love this free list of growing companies that insiders are buying.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
投资一家能够扭转命运的公司所带来的兴奋,对一些投机者来说是一个巨大的吸引力,因此,即使是没有收入、没有利润、业绩不佳的公司,也能设法找到投资者。有时,这些故事可能会蒙蔽投资者的头脑,导致他们以自己的情绪投资,而不是投资于良好的公司基本面。一家亏损的公司还没有用盈利来证明自己,最终外部资本的流入可能会枯竭。
因此,如果这种高风险和高回报的想法不适合,你可能会对盈利的、成长型的公司更感兴趣,比如莱佛士医疗集团(新加坡证券交易所代码:BSL)。现在,这并不是说该公司提供了最好的投资机会,但盈利能力是商业成功的关键组成部分。
查看我们对莱佛士医疗集团的最新分析
莱佛士医疗集团的增长速度有多快?
市场在短期内是一台投票机,但从长期来看是一台称重机,所以你可以预期股价最终会跟随每股收益(EPS)的结果。因此,有经验的投资者在进行投资研究时密切关注公司每股收益是合理的。莱佛士医疗集团设法在三年内以每年15%的速度增长每股收益。这是一个相当不错的比率,如果公司能够维持下去的话。
营收增长是一个很好的指标,表明增长是可持续的,再加上高息税前利润(EBIT)利润率,这是一家公司在市场上保持竞争优势的绝佳方式。莱佛士医疗集团股东的音乐是,在过去12个月中,息税前利润从15%增长到19%,收入也呈上升趋势。这两个都是衡量潜在增长的很好的指标。
下面的图表显示了该公司的利润和收入是如何随着时间的推移而变化的。点击图表查看确切的数字。
新交所:BSL收益和收入历史2022年9月14日虽然我们活在当下,但毫无疑问,在投资决策过程中,未来是最重要的。那么,为什么不查看这张为莱佛士医疗集团描绘未来每股收益估计的互动图表呢?
莱佛士医疗集团内部人士是否与所有股东一致?
投资者总是在寻求对他们持有的公司投下信任票,而内幕购买是市场乐观的关键指标之一。这是因为内幕收购往往表明,那些与公司关系最密切的人相信股价会有良好的表现。然而,小额收购并不总是表明坚定的信念,内部人士也不总是正确的。
去年,对莱佛士医疗集团来说,一个闪亮的积极因素是,某个内部人士怀着充分的热情购买股票。具体地说,在一笔大型交易中,执行主席兼首席执行官崔永路以每股1.19新元的价格收购了180万新元的股票。看到对公司如此高的信心,对股东来说是一个巨大的积极因素,应该会让他们对自己的使命充满信心。
除了内部人士收购,莱佛士医疗集团的另一个令人鼓舞的迹象是,内部人士作为一个集团拥有相当大的股份。我们注意到,他们在该公司令人印象深刻的股份价值3.3亿新元。这相当于公司13%的股份,这让内部人士变得强大,并与其他股东结盟。看起来对投资者来说非常乐观。
莱佛士医疗集团值得关注吗?
正如前面提到的,莱佛士医疗集团是一项不断增长的业务,这是令人鼓舞的。更好的是,内部人士是大股东,他们一直在买入更多股票。这使该公司成为你观察名单的首选--也可以说是研究重点。当然,识别优质企业只是成功的一半;投资者需要知道股票是否被低估了。所以你可能会考虑这个免费莱佛士医疗集团现金流贴现估值。
还有很多其他公司让内部人士买进股票。所以,如果你喜欢莱佛士医疗集团的声音,你可能会喜欢这个免费内部人士正在收购的成长型公司名单。
请注意,本文中讨论的内幕交易指的是相关司法管辖区内的应报告交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧